Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

Epic's platform, which it calls No Cell Left Behind, involves lysing red blood cells from a sample and spinning the remaining nucleated cells into a pellet, which is then resuspended and spread out into a monolayer where each cell is fixed in a particular location on a slide representing the complete cellular content of the blood at the time of collection. Immunofluorescent staining and imaging is then used to identify CTCs against the large background of normal cells.

 

Read the full GenomeWeb Story here